UniProtKB/Swiss-Prot Q9C019: Variant p.Ile29Val

E3 ubiquitin-protein ligase TRIM15
Gene: TRIM15
Feedback?

Variant information Variant position:

29 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Isoleucine (I) to Valine (V) at position 29 (I29V, p.Ile29Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs17194460 [ dbSNP | Ensembl ]

Sequence information Variant position:

29 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

465 The length of the canonical sequence.
Location on the sequence:

VVHELPACTLCAGPLEDAVT I PCGHTFCRLCLPALSQMGAQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VVHELPACTLCAGPLEDAVTIPCGHTFCRLCLPALSQMGAQ

Rhesus macaque                VVHELPACTLCVGPLEDAVTAPCGHTFCRLCLPTLSQMGAQ

Chimpanzee                    VVHELPACTLCAGPLEDAVTVPCGHTFCRLCLPALSQMGAQ

Pig                           --HKGAVCSDCQGRLEDAVTAACGHTFCRLCLPLPPQMGAQ

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 465	E3 ubiquitin-protein ligase TRIM15
Zinc finger	16 – 61	RING-type

Literature citations
The tripartite motif family identifies cell compartments.
Reymond A.; Meroni G.; Fantozzi A.; Merla G.; Cairo S.; Luzi L.; Riganelli D.; Zanaria E.; Messali S.; Cainarca S.; Guffanti A.; Minucci S.; Pelicci P.G.; Ballabio A.;
EMBO J. 20:2140-2151(2001)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2); VARIANT VAL-29; Isolation of novel non-HLA gene fragments from the hemochromatosis region (6p21.3) by cDNA hybridization selection.
Goei V.L.; Parimoo S.; Capossela A.; Chu T.W.; Gruen J.R.;
Am. J. Hum. Genet. 54:244-251(1994)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANT VAL-29; Genome diversity in HLA: a new strategy for detection of genetic polymorphisms in expressed genes within the HLA class III and class I regions.
Shiina T.; Ota M.; Katsuyama Y.; Hashimoto N.; Inoko H.;
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANT VAL-29;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.